^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

istiratumab (MM-141)

i
Other names: MM-141, MM 141
Associations
Company:
Ipsen
Drug class:
HER3 inhibitor, IGF-1R inhibitor
Associations
almost4years
Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE). (PubMed, Ann Oncol)
Istiratumab failed to improve the efficacy of SOC chemotherapy in this patient setting. High serum IGF-1 levels did not appear to be an adverse prognostic factor when compared with non-biomarker-selected historic controls.
Clinical • P2 data • Journal
|
ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
|
gemcitabine • albumin-bound paclitaxel • istiratumab (MM-141)